SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing...

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy


"Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy

Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’ platform to advance durable, safe and affordable non-viral gene therapies

Financing concurrent with strengthening of board of directors and scientific advisory board..."


030221 SalioGen Therapeutics Announces C
.
Download • 94KB


Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC